(2R,5S,11S,14S,19S,22E)-19-hydroxy-2,11-dimethyl-14-propan-2-yl-15-oxa-3,9,12,30,33-pentazatetracyclo[22.5.3.15,9.027,31]tritriaconta-1(30),22,24(32),25,27(31),28-hexaene-4,10,13,16-tetrone

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (2R,5S,11S,14S,19S,22E)-19-hydroxy-2,11-dimethyl-14-propan-2-yl-15-oxa-3,9,12,30,33-pentazatetracyclo[22.5.3.15,9.027,31]tritriaconta-1(30),22,24(32),25,27(31),28-hexaene-4,10,13,16-tetrone
• 化学式: C₃₂H₄₃N₅O₆
• 分子量: 593.7
• InChiKey: SBQJMEFFWMAILI-ZDKUCFCQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  43
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  150
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Toll like receptor modulator compounds
  申请人：Gilead Sciences, Inc.

  公开号：US10285990B2

  公开（公告）日：2019-05-14

  The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

  本公开总体上涉及类收费受体调节剂化合物，如二氨基吡啶并[3,2 D]嘧啶化合物和药物组合物，除其他外，它们可调节类收费受体（如 TLR-8），以及制造和使用它们的方法。
• Macrocyclic inhibitors of flaviviridae viruses
  申请人：Cypralis Limited

  公开号：US10472392B2

  公开（公告）日：2019-11-12

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

  本文提供了式 I 的化合物及其药学上可接受的盐类和酯类。 所提供的化合物、组合物和方法可用于治疗病毒感染，尤其是丙型肝炎感染。
• COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
  申请人：GILEAD PHARMASSET LLC

  公开号：US20140212491A1

  公开（公告）日：2014-07-31

  Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
• METHODS OF TREATING HEPATITIS C VIRUS INFECTION IN SUBJECTS WITH CIRRHOSIS
  申请人：Gilead Pharmasset LLC

  公开号：US20150150897A1

  公开（公告）日：2015-06-04

  Methods of treating hepatitis C virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of Compound 1.
• MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
  申请人：Selcia Limited

  公开号：US20170190734A1

  公开（公告）日：2017-07-06

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.